FY2027 EPS Forecast for X4 Pharmaceuticals Cut by Analyst

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) – Brookline Capital Management decreased their FY2027 earnings per share estimates for shares of X4 Pharmaceuticals in a research note issued to investors on Thursday, February 6th. Brookline Capital Management analyst L. Cann now expects that the company will earn $0.36 per share for the year, down from their prior estimate of $0.42. The consensus estimate for X4 Pharmaceuticals’ current full-year earnings is ($0.68) per share.

A number of other equities research analysts have also issued reports on the stock. Stifel Nicolaus dropped their target price on shares of X4 Pharmaceuticals from $5.00 to $4.00 and set a “buy” rating for the company in a report on Thursday, November 14th. HC Wainwright reaffirmed a “buy” rating and set a $1.50 price objective on shares of X4 Pharmaceuticals in a research note on Friday.

X4 Pharmaceuticals Trading Down 3.8 %

XFOR stock opened at $0.51 on Monday. The business’s 50-day moving average is $0.59 and its 200 day moving average is $0.60. X4 Pharmaceuticals has a 12-month low of $0.26 and a 12-month high of $1.60. The stock has a market cap of $86.88 million, a price-to-earnings ratio of -5.66 and a beta of 0.12. The company has a current ratio of 4.89, a quick ratio of 4.80 and a debt-to-equity ratio of 1.26.

Institutional Trading of X4 Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the company. GSA Capital Partners LLP acquired a new position in shares of X4 Pharmaceuticals during the 3rd quarter worth about $340,000. AQR Capital Management LLC lifted its stake in X4 Pharmaceuticals by 1,080.3% during the second quarter. AQR Capital Management LLC now owns 424,042 shares of the company’s stock worth $246,000 after purchasing an additional 388,115 shares during the last quarter. State Street Corp boosted its holdings in X4 Pharmaceuticals by 6.8% in the third quarter. State Street Corp now owns 2,952,895 shares of the company’s stock valued at $1,976,000 after purchasing an additional 189,105 shares in the last quarter. Barclays PLC increased its stake in X4 Pharmaceuticals by 196.0% in the third quarter. Barclays PLC now owns 277,682 shares of the company’s stock valued at $185,000 after purchasing an additional 183,861 shares during the last quarter. Finally, SG Americas Securities LLC raised its holdings in X4 Pharmaceuticals by 233.0% during the fourth quarter. SG Americas Securities LLC now owns 183,152 shares of the company’s stock worth $134,000 after purchasing an additional 128,148 shares in the last quarter. Institutional investors and hedge funds own 72.03% of the company’s stock.

Insider Activity

In other news, CEO Paula Ragan sold 76,473 shares of the stock in a transaction dated Friday, January 24th. The shares were sold at an average price of $0.45, for a total transaction of $34,412.85. Following the sale, the chief executive officer now owns 1,087,386 shares of the company’s stock, valued at approximately $489,323.70. This represents a 6.57 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Adam S. Mostafa sold 74,773 shares of X4 Pharmaceuticals stock in a transaction that occurred on Friday, January 24th. The shares were sold at an average price of $0.45, for a total transaction of $33,647.85. The disclosure for this sale can be found here. In the last three months, insiders have sold 202,663 shares of company stock valued at $91,198. Company insiders own 1.62% of the company’s stock.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.